NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021)
NeuroPace (NPCE) recorded quarterly Preferred Stock Liabilities of $141.4 million in Q1 2021, little changed quarter-over-quarter from $141.4 million in Q4 2020, and up 92.23% on a YoY basis from $73.6 million in Q1 2020.
NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
NeuroPace's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $141.4 million for Q1 2021.
- In Q1 2021, Preferred Stock Liabilities rose 92.23% year-over-year to $141.4 million; the TTM figure through Mar 2021 stood at $141.4 million (up 92.23% YoY), while the FY2020 annual figure was $141.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $141.4 million for Q1 2021 at NeuroPace, roughly flat from $141.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $141.4 million in Q3 2020 to a low of $73.5 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | NeuroPace | 527.50 Mn | 473.52 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 141.42 Mn |
| Dec 31, 2020 | 141.42 Mn |
| Sep 30, 2020 | 141.42 Mn |
| Jun 30, 2020 | 73.45 Mn |
| Mar 31, 2020 | 73.57 Mn |